Generic Advair Diskus Availability

See also: Generic Advair HFA

Advair Diskus is a brand name of fluticasone/salmeterol, approved by the FDA in the following formulation(s):

ADVAIR DISKUS 100/50 (fluticasone propionate; salmeterol xinafoate - powder; inhalation)

  • Manufacturer: GLAXO GRP LTD
    Approval date: August 24, 2000
    Strength(s): 0.1MG/INH;EQ 0.05MG BASE/INH [RLD]
  • Manufacturer: GLAXO GRP LTD
    Approval date: August 24, 2000
    Strength(s): 0.25MG/INH;EQ 0.05MG BASE/INH [RLD]
  • Manufacturer: GLAXO GRP LTD
    Approval date: August 24, 2000
    Strength(s): 0.5MG/INH;EQ 0.05MG BASE/INH [RLD]

Has a generic version of Advair Diskus been approved?

No. There is currently no therapeutically equivalent version of Advair Diskus available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Advair Diskus. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Inhalation device
    Patent 5,873,360
    Issued: February 23, 1999
    Inventor(s): Davies; Michael Birsha & Hearne; David John & Rand; Paul Kenneth & Walker; Richard Ian
    Assignee(s): Glaxo Group Limited
    An inhalation device is described for use with a medicament pack in which at least one container for medicament in powder form is defined between two sheets peelably secured to one another. The device comprises means for peeling the sheets apart at an opening station to open the container; and an outlet, communicating with the opened container, through which a user can inhale medicament in powder form from the opened container.
    Patent expiration dates:
    • February 23, 2016
      ✓ 
      Drug product
    • August 23, 2016
      ✓ 
      Pediatric exclusivity

See also...

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Advertisement
Close

Recommended

(web3)